allogeneic gamma-delta t-lymphocytes tcb-008
Generic: Allogeneic Gamma-delta T-lymphocytes TCB-008
allogeneic gamma-delta t-lymphocytes tcb-008: 1 clinical trial tracked.
allogeneic gamma-delta t-lymphocytes tcb-008 evidence translation
What we can confirm
1 tracked trial
No verified listed company relationship
What it means
AI will separate confirmed drug evidence from unknown company context.
What to watch
Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected
Prepared research question
What is verified about allogeneic gamma-delta t-lymphocytes tcb-008, and what remains unknown?
Run cited research
Traceable citations · Unknowns marked
See linked entities and source evidence2 indications · 0 study sponsors
Related indications
Study sponsors
No additional listed-company sponsor is linked.
Clinical Trial Registry Records (1)
ACHIEVE - An Adaptive Trial of the Efficacy and Effectiveness of Adoptive Cellular tHerapy wIth Ex-Vivo Expanded Allogeneic γδ T-lymphocytes (TCB008) for Patients With Refractory or Relapsed Acute Myeloid Leukaemia (AML)
Primary endpoint: Reduction in myeloblast levels in response to TCB008 dosing
Interventionalopen16 targetStarted 2022-08Completion 2025-076 sites · United KingdomTC Biopharm